On Monday, X4 Pharmaceuticals Inc (NASDAQ: XFOR) was -4.70% drop from the session before settling in for the closing price of $1.49. A 52-week range for XFOR has been $1.38 – $26.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 47.41%. When this article was written, the company’s average yearly earnings per share was at -71.40%. With a float of $3.89 million, this company’s outstanding shares have now reached $7.96 million.
Let’s determine the extent of company efficiency that accounts for 143 employees. In terms of profitability, gross margin is 83.0%, operating margin of -323.09%, and the pretax margin is -310.1%.
X4 Pharmaceuticals Inc (XFOR) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward X4 Pharmaceuticals Inc stocks. The insider ownership of X4 Pharmaceuticals Inc is 32.74%, while institutional ownership is 29.80%. The most recent insider transaction that took place on May 16 ’25, was worth 2,561. In this transaction Chief Commercial Officer of this company bought 1,032 shares at a rate of $2.48, taking the stock ownership to the 25,337 shares. Before that another transaction happened on Nov 15 ’24, when Company’s Chief Commercial Officer bought 13,404 for $0.34, making the entire transaction worth $4,598. This insider now owns 129,173 shares in total.
X4 Pharmaceuticals Inc (XFOR) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -5.4 earnings per share (EPS) during the time that was less than consensus figure (set at -5.16) by -0.24. Wall Street market experts anticipate that the next fiscal year will bring earnings of -2.69 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -71.40% per share during the next fiscal year.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Trading Performance Indicators
You can see what X4 Pharmaceuticals Inc (XFOR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -14.80, a number that is poised to hit -3.77 in the next quarter and is forecasted to reach -13.46 in one year’s time.
Technical Analysis of X4 Pharmaceuticals Inc (XFOR)
Looking closely at X4 Pharmaceuticals Inc (NASDAQ: XFOR), its last 5-days average volume was 0.74 million, which is a jump from its year-to-date volume of 0.43 million. As of the previous 9 days, the stock’s Stochastic %D was 8.12%.
During the past 100 days, X4 Pharmaceuticals Inc’s (XFOR) raw stochastic average was set at 0.85%, which indicates a significant decrease from 7.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.2142 in the past 14 days, which was lower than the 0.4198 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.2209, while its 200-day Moving Average is $9.4956. However, in the short run, X4 Pharmaceuticals Inc’s stock first resistance to watch stands at $1.5200. Second resistance stands at $1.6200. The third major resistance level sits at $1.7050. If the price goes on to break the first support level at $1.3350, it is likely to go to the next support level at $1.2500. Now, if the price goes above the second support level, the third support stands at $1.1500.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Key Stats
There are 5,789K outstanding shares of the company, which has a market capitalization of 16.20 million. As of now, sales total 2,560 K while income totals -37,450 K. Its latest quarter income was 28,810 K while its last quarter net income were 280 K.
